Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LaBarre Michael J. | SVP, Chief Technical Officer | Feb 22 | Option Exercise | 0.00 | 8,803 | 0 | 145,488 | Feb 22 06:28 PM | Torley Helen | President and CEO | Feb 22 | Option Exercise | 0.00 | 39,354 | 0 | 556,671 | Feb 22 06:27 PM | Torley Helen | President and CEO | Feb 14 | Option Exercise | 0.00 | 28,729 | 0 | 531,560 | Feb 16 04:52 PM | Matsuda Masaru | SVP, General Counsel | Feb 12 | Option Exercise | 0.00 | 4,129 | 0 | 18,625 | Feb 12 07:10 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 12 | Option Exercise | 0.00 | 7,883 | 0 | 135,911 | Feb 12 07:07 PM | Torley Helen | President and CEO | Feb 12 | Option Exercise | 0.00 | 32,795 | 0 | 519,090 | Feb 12 07:06 PM | Torley Helen | President and CEO | Feb 10 | Option Exercise | 0.00 | 31,282 | 0 | 501,804 | Feb 12 07:06 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Feb 10 | Option Exercise | 0.00 | 8,134 | 0 | 130,934 | Feb 12 07:07 PM | Matsuda Masaru | SVP, General Counsel | Feb 10 | Option Exercise | 0.00 | 6,257 | 0 | 17,699 | Feb 12 07:10 PM | Torley Helen | President and CEO | Feb 01 | Option Exercise | 14.66 | 50,000 | 733,000 | 520,522 | Feb 01 06:55 PM | Kelley Kenneth J | Director | Feb 01 | Sale | 48.12 | 5,000 | 240,594 | 189,833 | Feb 01 06:56 PM | Torley Helen | President and CEO | Feb 01 | Sale | 47.84 | 50,000 | 2,391,918 | 470,522 | Feb 01 06:55 PM | Kelley Kenneth J | Director | Jan 04 | Sale | 42.91 | 5,000 | 214,556 | 194,833 | Jan 04 05:07 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Dec 21 | Sale | 42.58 | 12,000 | 510,919 | 122,800 | Dec 21 06:01 PM | Kelley Kenneth J | Director | Dec 07 | Sale | 41.00 | 35,086 | 1,438,526 | 199,833 | Dec 07 06:05 PM | Kelley Kenneth J | Director | Dec 02 | Sale | 41.00 | 31,792 | 1,303,472 | 234,919 | Dec 02 05:55 PM | Kelley Kenneth J | Director | Nov 27 | Sale | 41.25 | 10,000 | 412,500 | 266,711 | Nov 27 05:43 PM | Torley Helen | President and CEO | Nov 25 | Option Exercise | 14.66 | 50,000 | 733,000 | 530,522 | Nov 25 06:56 PM | Kelley Kenneth J | Director | Nov 25 | Sale | 41.50 | 9,671 | 401,350 | 276,711 | Nov 27 05:43 PM | Daly James M | Director | Nov 25 | Sale | 40.41 | 10,363 | 418,800 | 21,002 | Nov 25 06:57 PM | Henderson Jeffrey William | Director | Nov 25 | Sale | 40.08 | 24,498 | 981,757 | 47,609 | Nov 25 06:59 PM | Torley Helen | President and CEO | Nov 25 | Sale | 40.73 | 50,000 | 2,036,568 | 480,522 | Nov 25 06:56 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Nov 20 | Sale | 38.76 | 12,000 | 465,176 | 134,800 | Nov 20 06:25 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Oct 20 | Sale | 30.43 | 12,000 | 365,148 | 146,800 | Oct 20 04:53 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Sep 21 | Sale | 26.91 | 12,000 | 322,884 | 158,800 | Sep 21 07:30 PM | MATSUI CONNIE | Director | Sep 11 | Sale | 27.06 | 32,000 | 865,792 | 216,753 | Sep 14 05:33 PM | Matsuda Masaru | SVP, General Counsel | Sep 04 | Option Exercise | 0.00 | 6,884 | 0 | 13,822 | Sep 04 06:13 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Aug 20 | Sale | 28.30 | 12,000 | 339,564 | 170,800 | Aug 20 04:21 PM | Daly James M | Director | Aug 13 | Sale | 29.12 | 34,337 | 999,893 | 31,365 | Aug 13 06:43 PM | LaBarre Michael J. | SVP, Chief Technical Officer | Jul 20 | Sale | 29.01 | 12,000 | 348,072 | 182,800 | Jul 20 06:33 PM | LaBarre Michael J. | SVP, Chief Technical Officer | May 22 | Option Exercise | 7.14 | 18,613 | 132,897 | 194,800 | May 22 06:39 PM | LaBarre Michael J. | SVP, Chief Technical Officer | May 20 | Option Exercise | 7.14 | 21,387 | 152,703 | 197,574 | May 21 04:11 PM | LaBarre Michael J. | SVP, Chief Technical Officer | May 20 | Sale | 23.80 | 21,387 | 509,075 | 176,187 | May 21 04:11 PM | Kelley Kenneth J | Director | Mar 19 | Buy | 14.23 | 52,629 | 748,697 | 277,553 | Mar 19 07:28 PM |
|